Efficacy of Low-dose Gliclazide in Patients with Type 2 Diabetes Previously Treated with Rapid-acting Insulinotropic Agent or Sulfonylurea other than Gliclazide

DOI Web Site 12 References
  • Shimoda Masashi
    Division of Diabetes and Endocrinology, Department of Medicine, Kawasaki Medical School
  • Hayakawa Naomasa
    Division of Diabetes and Endocrinology, Department of Medicine, Kawasaki Medical School
  • Tatsumi Fuminori
    Division of Diabetes and Endocrinology, Department of Medicine, Kawasaki Medical School
  • Tawaramoto Kazuhito
    Division of Diabetes and Endocrinology, Department of Medicine, Kawasaki Medical School
  • Shigetoh Makoto
    Division of Diabetes and Endocrinology, Department of Medicine, Kawasaki Medical School
  • Kanda Yukiko
    Division of Diabetes and Endocrinology, Department of Medicine, Kawasaki Medical School
  • Kawasaki Fumiko
    Division of Diabetes and Endocrinology, Department of Medicine, Kawasaki Medical School
  • Hashiramoto Mitsuru
    Division of Diabetes and Endocrinology, Department of Medicine, Kawasaki Medical School
  • Matsuki Michihiro
    Division of Diabetes and Endocrinology, Department of Medicine, Kawasaki Medical School
  • Kaku Kohei
    Division of Diabetes and Endocrinology, Department of Medicine, Kawasaki Medical School

Bibliographic Information

Other Title
  • 2型糖尿病薬物治療における低用量グリクラジドの有用性
  • 2型糖尿病薬物治療における低用量グリクラジドの有用性--速効型インスリン分泌促進薬あるいは他のSU薬からの切り替え症例による検討
  • 2ガタ トウニョウビョウ ヤクブツ チリョウ ニ オケル テイヨウリョウ グリクラジド ノ ユウヨウセイ ソッコウガタ インスリン ブンピツ ソクシンヤク アルイワ タ ノ SUヤク カラノ キリカエ ショウレイ ニ ヨル ケントウ
  • —速効型インスリン分泌促進薬あるいは他のSU薬からの切り替え症例による検討—

Search this article

Abstract

Type 2 diabetic patients previously treated with rapid-acting insulinotropic agent (glinide) or a sulfonylurea other than gliclazide, were treated with low-dose gliclazide (less than 40 mg, daily dose) for 12 months to counter poor glycemic control or hypoglycemic events, and efficacy was evaluated. Subjects were 13 randomly selected patients previously treated with glinide (glinide group) and 14 treated with sulfonylurea (SU group). The glinide group's average age was 65.6 years, BMI 24.3 kg/m2, and diabetes duration 11.0 years at baseline. The SU group's average age was 67.1 years, BMI 23.4 kg/m2, and diabetes duratiun 18.1 years at baseline. HbA1c in the glinide group decreased significantly from 8.5±0.5% at baseline to 7.0±0.4% at 12 months end points (p<0.005 vs baseline). HbA1c in the SU group decreased from 7.6±0.5% to 7.1±0.4% (p=0.141 vs baseline), and a significant weight reduction was observed (p<0.05). No episode of hypoglycemia was reported during observation in either group. Results suggest that low-dose gliclazide is useful in treating type 2 diabetes.

Journal

References(12)*help

See more

Keywords

Details 詳細情報について

Report a problem

Back to top